Literature DB >> 14684337

Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor.

Yvonne Yip1, Frantz Victor, Jason Lamar, Robert Johnson, Q May Wang, Donna Barket, John Glass, Ling Jin, Lifei Liu, Daryl Venable, Mark Wakulchik, Congping Xie, Beverly Heinz, Elcira Villarreal, Joe Colacino, Nathan Yumibe, Mark Tebbe, John Munroe, Shu-Hui Chen.   

Abstract

We describe herein the design, syntheses and evaluation of a number of bicycloproline P2 bearing HCV protease inhibitors endowed with impressive enzyme potency, enzyme selectivity, cellular activity and favorable ADME profiles.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14684337     DOI： 10.1016/j.bmcl.2003.09.074

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  6 in total

1.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

Review 2.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

3.  Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Authors:  Hongmei Mo; Liangjun Lu; Tami Pilot-Matias; Ron Pithawalla; Rubina Mondal; Sherie Masse; Tatyana Dekhtyar; Teresa Ng; Gennadiy Koev; Vincent Stoll; Kent D Stewart; John Pratt; Pam Donner; Todd Rockway; Clarence Maring; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Authors:  Robert B Perni; Susan J Almquist; Randal A Byrn; Gurudatt Chandorkar; Pravin R Chaturvedi; Lawrence F Courtney; Caroline J Decker; Kirk Dinehart; Cynthia A Gates; Scott L Harbeson; Angela Heiser; Gururaj Kalkeri; Elaine Kolaczkowski; Kai Lin; Yu-Ping Luong; B Govinda Rao; William P Taylor; John A Thomson; Roger D Tung; Yunyi Wei; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

5.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  Coupling Interrupted Fischer and Multicomponent Joullié-Ugi to Chase Chemical Diversity: from Batch to Sustainable Flow Synthesis of Peptidomimetics.

Authors:  Antonella Ilenia Alfano; Elisabetta Buommino; Maria Grazia Ferraro; Carlo Irace; Angela Zampella; Heiko Lange; Margherita Brindisi
Journal:  ChemMedChem       Date:  2021-10-18       Impact factor: 3.540
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.